a filing, and for expected set PDUFA, the at obe-cel.
We with an the target And also of November important with well. to quarter but I'll call. is acceptance first a obviously, event the started lot our also of start It's -- was to very with of everybody, very which updates for BLA you our overall obviously welcome, thank year XX. a successful and least as quite which now Well, quarter. Olivia, much, activity obviously, been the corporate obe-cel, date lot the related out
filing managed towards to by the -- European of the the also accepted. get quarter We the end
company filings or MHRA that very had very both led successful the was the and for we resulted important hold. is license the because a major it a both prerequisite and also So supply under clinical is commercialization the jurisdictions able this the to of facility important the was deliver inspection review. now us in from by that that have be need facility.
What's product commercial is towards of to there -- was What that to Nucleus preparedness Nucleus the from and we actually facility for to we understand to actually necessary license commercially a overall actually
through getting as accomplishment, obviously, for up full successfully and the well with well the both first us agency. with interactions as the that, FDA inspection process, European So the that completing was and in huge ongoing review very a sets
study and dose in Phase confirmation obviously involved our We patients. first I also during the quarter the also in started SLE
data the -- June, or important ASCO the be the are end at May beginning Now when you we updates at and think have middle now EHA, meetings, next updates, are to about with results FELIX as confirmation particular the impact as impact outcome. follow-up cell well the the and patients updated the for a that study of received presentation stem of have on oral an transplant have may focus we the both of of which at at persistence that longer of going
study. of cells CAR the measure in in to the of will the posters. T impact EHA, One inotuzumab-based in regimens outcome presence further bridging trial. that And second that the sensitive looks methodologies analysis at at the and be X also to linking Now persistence of in presented to then addition, have is we the determine form
agency middle by course lot in as target November. the a both it for very the the the which further review the sets significant date trajectory well of amount very on good of European the accomplishments well year, the of a very for up of program, us also through this sets PDUFA and FDA So update, and of us
Now year, frame side, X on a resulted the operational early corporate this which leading obviously, time in February the announcements. in activity there lot was of into
the which the our technology activities their that terms AUTOXNG. one lead of of of the to these one commercial launch X of that that strategic the and looking options cornerstone obviously, this pivotal therapy start treatment time we've those have very providing The for to applications, relationships have, side, area set Nucleus at program. first particularly addition we're certain points technology the There It's collaboration announcement obviously are with the other There Both pipeline in before but was to each have an and That's study side.
We the launch for is BioNTech around access of We option the to to the AUTOX/XX to related the are lead BioNTech, manufacturing on as part program that a programs. context look area well. in significant vivo of in exercise then use areas we access of CAR access developed, also on key including building. also collaboration. those modalities for of an with then cell approaches, is programs. our of options are important will were in facility support the T closely, support of of also
excited comprehensive having very a relationship we're that the the it's that and we're building, BioNTech. with interactions and So about relationship we're very
but million we sets transaction, the BioNTech markets Now balance significant to for with added our the Between obviously us transaction we of footprint that expand deliver capital. particularly and the obe-cel. gives in transaction for did parallel very the or also expansion $XXX which obe-cel, growth And for X added additional capital on the a obviously the following indications, to also just us business. launch to sheet, the transactions of ability gives a well future up and to opportunity
the well in this as strong Johnson John experience. very as and level over had, quarter, Mike Chair immunology markets both a advertise of that Ravi we of terms alongside had transformation addition, to stage very Rao from particularly development company an the with base actually the aspect that had, a who's Now Leiderman transitioning last Board. kind at of and Board actually joined, experience a in commercial Bob sort Bonney, the company. we of level also strong have taken joined and the the we're stage of We also from experience expert then as commercial on autoimmune of joined And end and the the who's the operating also of experience obviously, at and of Azelby as that year, have, company the capital Lis and go diseases transitioned that
up So forward-looking set we're and a company to company we're sort a a a commercial-stage indications. making of that of becoming the very part broader of important the well company starts into transition set getting very also that expanding and sure
least What you we're that, Slide this but are the our of #X. actually just FELIX of bit, to outside helpful back on kind like well out obe-cel we environment in FELIX at this the what U.S. and Nucleus thought quite at and at getting U.S. And possible might just be with you kind the which to start Now and the or actually moving with illustrate in is, answer the as the look actually ensure that actually of one is I'd that -- did manufacturing in. up do built U.K. even study is as well, to guys product how a facility I deliver actually to of actually can remember questions do of within -- one actually with what you study
see you terms conducted the of XXXX goes pandemic, the reported coincides with the area, that say various the actual period XXXX as would a so over shaded of study.
I the is what basically key the to XXXX, of for the end the towards line that and enrollment from of -- were that in from you see see the that, XXXX across blue so peaks of And globe. you study time the of the entire was in the middle time types of we've seen COVID-XX can majority infection all the
what huge on for taking reach data And that the entire elsewhere you U.K. ability have you U.S. highly the on and clearly, logistics from is And this perspective green of the as a really basically because in manufacturing makes U.S. as of the the gone see, actually you and international out variability flights as available international internationally. manufacturing to flights line clearly, number that government. obviously the side. can in actually our flights Now well period. from very place from challenging based This the is was site every in during of number also a reliant us U.S. see have the in period being
wait favor you line.
But the fact, the the is the access, in ranges you given and of gave you terms systems actually is but on and been reality pandemic, we international has obviously see our are our where of virtually their is airlines terms into shut II on challenging range to the look actually those time. have so quite have then to over have things middle, that these on stability not of moving that we literally all limitations able actual you bit actually That's that of and have the when fever that it that to see, but internationally products were go that good many but period. lot days, only time pressure logistics.
This centers, end a one delivery to the flights most is actually people way. so extreme ability have have we the a the money delivered remarkable forth, at the traveling many that with in have in is not to would every that the base of advantage deliver quite and the throughout in going that Phase despite serve the we been of in so learned and put that's us actual an actually have the to kind curve variability, be for of know, actually is of the pandemic of delivery things of for And this actually low on single one what the was down all challenges and entire on, that clinical it plotted that on particular Now And infections, flights period impact make means the an place is robustness huge XX see obviously a of obviously our and that asset on also in priority. a time. we tested for one every through XX of that able had you on small us flights time And have confidence do in gives product. no shutdowns of you expected actual upper the this days And what of that end we conduct, jagged the
up go which and that this largest what X% categories all Now reminder study. somewhere that the just disease, acute think cohort a is to burden in as what obviously study disease range have close between want in that a way we're we leukemia. I with A, the risk the actually matter patients to of which actually slide, of of study thing patients the And if there all included is to And the do point Slide the sales group, brief have FELIX to I the relapsed/refractory that looking XXX%. we next is lymphoblastic the first that to X, is have are were out
very entire this bucket of have we high disease. levels So of
extramedullary that actually cohort the basically typically fight of relapse NGS actually to it's levels, have also But could almost earlier a particularly the isolated analysis you basically called the settle were patients it patients obviously normally gain which middle B or the of has is disease have in important escape disease, marrow And a by to We and that the a PCR a are had of where actually then These the place the pick the because patients you little starts so in survive actually catching can up and also disease residual the by before in the have by is difficult patients low marrow, because grow did with and disease managed to very succeed just C have another relapses.
But pick function morph the where these have, levels cohort extent very minimal flow in disease and sequencing. out. a it's different the to in up. visibility are disease environment. you that disease, treat standard actually tissue certain which gain relapse to patients that group methodology bit last
are groups patients you you, is it doesn't to gives practice care that because studies. your resonates having. important the study see having clinical And quite from as of So the perspective as real-world a these as that, studies representation is ability often that world. all setting with possible. actually physicians real experience with quite study it this the sure when actually representation to treating you often is to different why of clinical actually physicians of it will protected think does. basically do that that a walk well also the maximize you patients what the and actually about a gives your have this Often in see selective. are this not is for, What them in -- They're And the you'll to this the make in remarkable And as stuff. represented outcome happen have you an we
that's patients on pandemic, were the of things what we've gave the XX% product. treated where out, conversation to the in of of of a aspect And number logistics. supply, the delivery. the studies actually level all control had of the the that across every is few that patients, than the every to higher prior on conducted you just part the study and of actually to tying We selection and the a managed with Now to logistics patients entirety of seen point prior
So tells the delivery alongside and it something just you robustness about study.
So we across stabilization at with that And to survival Slide looking that, a the of we're the that #X. see have indicative the you is indeed moving outcome. event-free What chance is like experience. here after may can entirety curve go as we certain the of that a patients actually period a looks a time, group for It of long-term to have curve. horizontal starts of that see,
and Now snapshot slide part the where will going be is that gives to we us of between of additional stabilization. underpins this presentation. update more to somewhere ASCO that have and X the also months curve is is at next X curve that This data follow-up the actually the where the part see much the snapshot, ASH the strong. Obviously, we're of stability in out EHA starting this are
And in be good this important update whether middle will data robustness will in give believe later a well. it year so of the we us because this also time points understanding very the as have indeed we the
see now we the you perspective. of you from lymphodepletion patients blue actually pretty pointed as at survival at, have intervention.
And lymphodepletion in these with patients the is what a side. curves, prior it one burden X% by giving burden the that can the And perspective, have patients line, that do look well. on of the you to prior event-free see from less at safety we're these start hand, expect good the the And presentations to these was things predictor are to efficacy that of burden. and can several again, that but as looking we the Now we these before also have an experience, but I'll than exceptionally patients do actually you we tumor will conversations may find types level did and looked disease remember, a one of leukemic on out we efficacy
-- of we the the response the very tumor to it's are X% the also very the low patient a in very that a wide long-term burden see to only us, green us gives curve, rate, not that up Below high not marrow. a but it range to outcome patients. burden patients right a XX% in that, such attractive give these but in of extreme range tumor in group. So the overall burden in of to tumor does obviously, going
struggle can But see these green as in which have see is that well, could stabilization a clearly see more the by that patients disease they controlled you that a you disease. have than more also is see, the burden the are ones groups do refractory the XX% more you by still other the that very orange the definition, these at do patients. not patients where group as remarkably you than therapy, you nature of have curve, lymphodepletion that in encouraging.
Where almost which patients in And bridging patients struggle already be curve, lot of
Now the picture to overall seen an what have Blincyto. outcome you substantially is would for as here still different
power sense in we outcome. burden terms has patients on that, even you gives actually very that been also actual them the it patients the you good before to of have ways these finding very obviously, in it reduce in treating. significant tells So But therapy actually disease worst treat of the you a a impact
it's but see difference Now XX, side safety of only next not also also the when on there's you the we look in Slide slide, signals. that efficacy a on the
syndrome left-hand Now high-grade what's data you these across on see is standing out see small. all the of ICANS high-grade are totality And And we obviously areas are very patients. or which release side, patients. the patients the the cytokine that dark the the blue
engaging substantially X% So or T X% they're is therapies which are CAR other of levels and the the below in low, T type the any cell space.
we attractive disease actually the very see a profile. impact then But at X% get than patients look no ICANS, high-grade in can less at disease the we high-grade side, or that of no ICANS event we hematological that lymphodepletion, had a for have right-hand none when the overall CRS. So burden, for patients these event of high-grade on middle CRS both where burden the toxicity
do and an is It ICANS, the level some has if at which group look lymphodepletion. actually syndrome is somewhat population you of like similar what to CRS maybe well. then the does bridging a you're see of it's still to of do in low the still would therapy patients look the tumor level. experience overall see of you do now a release at time ICANS, you inside what above after at group, actually middle high-grade cytokine see an you increase that actually remarkably and but XX% middle If burden terms But relatively
differences perspective, event-free see but not outcome there, safety see also signals. the from of So do differences only also the you survival you risk in an in
be Now it burden patients the to low the an important obviously that look see feature the in also when I and data, important product be terms looks will we'll treat positioning well factor are safety the in of the forward, actually outcome you the on very an think at I predictable clearly, going of and of on be that well both terms which will look think that the as efficacy where and as disease but worked patients. to side very part manageable
of launch moving we terms range activities. about from have swing we're trajectory here making of the prepared Slide in quite a are commercial perspective. Now of to full regulatory Obviously, adequately been in we're Obviously, briefly talked readiness, sure milestone launch. wide about There #XX. a for
how You across organization side, overlaying we the the way in of regions a also sort working are of on that key kind sort of with U.S., of within see areas it's basically the those. regional preparation, basically X we're the left-hand manage view. That's the our we terms
et first affairs particularly with When with of awareness, of all, with frankly, in terms supporting, cetera, the engagement is activity, on, obviously, every communication, focused the centers, creating we medical it's that team. of we're through look whether payers, areas and in terms
work lot of a of So a and onboarding in airports, a activity of centers. very of of context the support focused engagements of of going and on, lot the the lot amount also, course, direct that's
visible demonstrating cetera, value of There's quite So stream that's of of publications. amount the significant and work around therapy. a the et activities.
A very that significant obviously because will in presentations very it lot result will at be a conferences, presence and
can understanding all because also important type sort are there's have we to that there's to an patient lymphodepletion, ability elements in of sort a cost a on impact from that profile, And you much also events. what the of expect on number more are such important when description huge a that a and there's a events treatments about to very do there's going hospitals and more perspective to actually of cost new is fact there. then support induce, plannable think actually payer. and resource of what we So safety a is those when to more the into to what and for old happen on there's disease not how are those the of translate important value, but you you the clinical reduction when overall on but have also also high-grade shorter The side. you what economic grade these and more we a at prepare plannable, That at That the an have drivers obvious CRS parameters from ICANS activity based on et in that impact aspects way is of of But perspective, important predictability, an burden But to think need a here at substantially huge hospital high-grade looking really lot utilization patient higher for. the valued. benefit anticipate only has the and have operating that's cetera. management.
And long-term describe and also a also about much
there's going that So segment. activity on lot a that's of in
to into. us relevant safety center a that I And on that in requires are and the think appropriately actually which into There conversations our of handled the cell from get the has and systems biggest lot holding key that whatever make that element board involved. work product the all to in also looking long-term perspective, onboarding be a probably management, lot managed delivery interaction are and is. a of the just a support outcome a that triaging corollary There's support of those we training the the point we're involved. it's required is in centers of terms of a stream the market terms management. side preparing the that is also support of is The whether on perspective, single through we're really handling can sure have, we centers the collection, to centers coordinator need is of and
So involved getting centers is centers crucial. from product. resonance center. interest from a the involved onboarded It absolutely takes very we're accredited very a of is also and time. it the the activity, and This the center, And takes the to of the the has willingness commitment pleased onboard to see product
products that in we and perspective lot complements preparation as before, in have So also implementation also delivery chain actually of the well. on of to is with and logistics, transaction close that the pieces us about a allows seen have it take need is the from we testing perspective is logistics. do. we for which to because to the of of mentioned very all talked an then infrastructure a have physician And the you we release ship backbone time, actually gives and the time place.
It that, to out process want ongoing some which us with some bank's as during place also that well and important already us element of patient What that There's well transaction obviously important That's Health. supply track. have an of Cardinal
obviously, we're on involved is we're a experienced the very preparation team engaged, kind work seeing the and fantastic that ground, doing, very this dynamic team, residence nice very good there. So and of very
next briefly the Nucleus. about the Moving just slide to and the talk manufacturing commercial facility,
we I of in week weeks actually, image took was in few ago. one the last few the the sunny in U.K. days It middle, the a the So had
So this the opportunity. was
industrial products. is facility XX,XXX a XX months. about to facility true this that of It's several MHRA production So went square a setup we groundbreaking the within approval foot for from really and therapy
the setup So would this in is validation actually design of a took us in in of facility functioning, I industry different a do, most that, good that also very delivery with be fully operation get and have very approaches our it allowed We very the a a mostly the into with terms the support this of launch. good in of inspected mode the facility ready of starting but facility of different a taken but position a colleagues to think facility. we put validated than and level very reduce remarkable with time strong point very fully the actually capacity a good be obviously us to to in to -- future massively did
with into give the sort then approach. And in the So with really a autoimmune the areas disease the oncology before, disease. layer are you've seen of of in to as next AUTOX, obe-cel just itself terms products slide as Slide XX, there daughters obviously with dual the us in a moving that, actually respective to of at us of with family and looking both opportunities well targeting of sort X obe-cel obe-cel AUTOX/XX human that allow opportunities
kind Slide to we autoimmune that it just XX, a if maybe on move when the comes to seeing in we're of Now particularly the words dynamics space, disease. few
every to tend think I about how is and a to to the has there communication it. and from lot to to space get coming out time And get you how of active paper a some and data hugely interpret happening. of So obviously we a tend things
compassionate mind important in I trials. in based today clinical general, not think look in is we that I data to keep all are almost think points at use, that what's
of we've impressive patients. frankly, certainly compelling, get quite outcomes very is that in actually patients that to these and no disease long-term data the long-term it given while and outcome So possible seen reversal was in not
very limited we know still low outcomes, is a product. obviously, but impressive very observation. So Most what numbers very of from Kymriah-like patient and
to to this observation. Kymriah closer with a we longer-term look that product that's all the the a manufacturing what the really receptor But when somewhat So is based process, ones has on way almost -- which CAR manufacture. at is particular we is identical all modified information
There's cetera. lot there's that the it approaches patient patient going in that antibodies of where all has a relapse were starting to one treated, still was we're where that obviously that but in after patient. is relapsed, phase far obviously to months. Of of be a in recurrence a learn we're visible but of Patient actually patients still happened where was, been myositis, clearly a in than the to reported XX opportunities limitations some the et lot SLE, we're are, these see And scleroderma, is the in learning that what have on. there's maybe are so better starting
that, keep I think that it of of remind salt grain -- at but amount data important exciting limited limited very ourselves basically it's data, of with and is amount very still I look data. think a with to certainly the
to to in a would patients, ability clarity B reset We the sustainable.
What Georg in at whether was seen seen improvement of Munich work to is and cell be in the be a work actually showing at -- given that use in that meaningful we colleagues a whether also without was indicating of seem the the he responses, a to would outcomes. sclerosis there published in Erlangen also about patients compartment same the University unclear obviously, the various to clinical longer-term recent single with an these of taken time, and that lot be explore obviously, that at was meaningful, these deep clearly approach. clearly lack of and was ability is But asked which actually interesting an it's there Schett gave to University would of now induce was see And activities we've actually your the which see patients done by outcomes obviously there this Erlangen, in of initial also indicated one interview patients. and an with was learned first inotuzumab, Erlangen, part was and have Cantor, our X at be good addition part actually which data,
of going an probably of certainly immune to get we forward, but variability an with that's lot outcomes. where And actually going will shops patient interesting in it's have be likely going there's as learn, of movement.
And we more a to where more autoimmune sort to things I do that So there's a highly to area very certainly how redose see be system in one think in, many be areas the think, I as mechanisms introduced active start of the the thinking is patient. to actually we're one
on was next kind used what briefly do slide, their to product the University work. I'd like the Now at of that just is the relationship between to Erlangen and for obe-cel of show the
treatment product pediatric I was pointed ALL and designed think is that is it's for used to the out, patients. very initially as the it I actually and of important, Kymriah similar
piece.
And So there's of the available we not trials. good quite data from Kymriah's product a knew data that surprisingly, actually was similar for in original set the very to data
long years in you of or remissions, reference. give persistence, the to of level you giving high activity, XX%, with the X X take was see And rate in Some persistence patients. Kymriah, these complete as molecular seen
The the initial likely On study the at original going at lower which some ALLCAR in there's data with or XXXX. ELIANA with side, the And set. the be Kymriah. actually experience summary Meeting pediatric with ASH of fuller the publication the a data the data the to presented the at -- published from point right-hand, the study, was what from is
of and remind very really called blue light is have an differentiation overall, green, to much reduction than that our in experience has. obe-cel the same and the differences like the key of rather between with is a activity delay sort that talk in can the but the our the we rate I'd affinity of the blue which significant targeting faster for product we similar what having the which from in which difference specificity that, with that blue see And is very product dark which between to high see fast perspective, the activity difference with product. and on in experience that having a slow toxicity an that CDXX. column, obviously you that's you used us product the obe-cel. ALL. could character, property particular also rate, the us quite product a in you we is you can as Now same off see see you in that alleviate toxicity in this in toxicity, terms of comparison also the level immunological of about the you rate, off-rate.
And that increased the And on obviously, study. is Kymriah, the heard as we XXX-fold columns in but see of bit, overall that binder CATXX gives our about for the product properties actually FMCXX, box From What gives ELIANA The binder design
to have that, the And safety thing is, position the in have autoimmune profile. very similarity, space. a the remarkable move with we're a Now attractive we believe we we obviously, better obviously into
to a pediatric long had the autoimmune is of shorter in in much patients. persisting this I'd highlight things like the ALL that persistence that One product
also it the that of a is you target with That's X patients. were to about. fact, long cells, leukemia. X difference target still of levels about patients to of is months on X cells X because low amount pediatric what available, thinking in to ALL you autoimmune months, persistence in which based extreme patients went X not available from persistence maximum in years or In target or folks is This get have true if not years X difference MRD-positive some
patients, in it actually sales fact that was the and I rapidly, immune in different the settings retirement we to the CAR. in And the system autoimmune the the and is patients for with consistent that actually to also clear the an the the difference immune them. the key up Now And patients the built or very before, was eventually reaction CDXX recognize those fact, their cleared between the was -- were ability fact, that response. the system assume by of attempt myositis corroborated the retreat predominantly indeed, a map difference is, immunological ability rejection. on disease with persistence mentioned to driver X And -- of with cells have that actually actually
also if a actually X pretty might and through with similarly, top think quite risk significant also the induce number about some there a that you in cell T Now been certainly as delivered immunogenicity products engagers products that has of past. and well you antibodies is
area have or more of in impact an profiles of watch certainly, actually approaches, the for than ability that an which time redose, some could that's to seems terms over of So important the to some the approaches others.
All right.
study, the So with of open QX. had opened during We Phase the the our going in to I that, Slide -- obviously, enrollment. course for first is center XX,
initial enrolled, for have you data on we We well we're and that towards to the patients have track now the guided the of X end year.
is for can need to We're enrollment, patients pediatric Just translate within is that DLT limitations the you, in right. or restrictions those cell types of to basically which without million periods a any fixed a this dose remind enroll the don't We a study. dose of confirmation actually XX adults, ALL do they but dose. come nature.
All as dose of we
are more also AUTOX/XX forward well.
All with So AUTOXNG AUTOX brought -- with the data. we're pipeline. the patients in just additional of active activity obviously, enrolling as view Certainly, for a on both of sort there's additional fast the a few -- program. with obviously, additional right. that, a we're And we of last And looking program, terms They those programs.
financial hand So and transition. with results, to I'd actually that, to We I'll to go Rob. like over
